Cantor Fitzgerald Reiterates “$21.00” Price Target for Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics Inc. (NASDAQ:ABEO) has been assigned a $21.00 target price by equities researchers at Cantor Fitzgerald in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 134.64% from the stock’s previous close.
A number of other brokerages also recently weighed in on ABEO. Jefferies Group LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Abeona Therapeutics in a research report on Thursday, June 1st. FBR & Co reiterated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, April 5th. BidaskClub upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Maxim Group set a $14.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 25th. Finally, Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $17.86.
Abeona Therapeutics (ABEO) traded up 0.56% on Tuesday, hitting $8.95. 484,856 shares of the stock traded hands. Abeona Therapeutics has a 12-month low of $2.33 and a 12-month high of $9.85. The company’s 50 day moving average price is $5.54 and its 200-day moving average price is $5.24. The stock’s market capitalization is $360.28 million.
Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Abeona Therapeutics had a negative net margin of 2,568.57% and a negative return on equity of 26.99%. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.28 million. Analysts predict that Abeona Therapeutics will post ($0.57) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/18/cantor-fitzgerald-reiterates-21-00-price-target-for-abeona-therapeutics-inc-abeo.html.
A number of hedge funds have recently bought and sold shares of the company. Private Advisor Group LLC boosted its stake in Abeona Therapeutics by 50.0% in the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 6,999 shares during the last quarter. A.R.T. Advisors LLC acquired a new stake in Abeona Therapeutics during the fourth quarter worth about $117,000. Family Management Corp acquired a new stake in Abeona Therapeutics during the first quarter worth about $120,000. Hikari Power Ltd acquired a new stake in Abeona Therapeutics during the first quarter worth about $150,000. Finally, Tudor Investment Corp Et Al acquired a new stake in Abeona Therapeutics during the fourth quarter worth about $162,000. 35.60% of the stock is owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.